BofA Elevates J&J Price Target Despite Predicting Q3 Earnings Miss
Yahoo Finance ·
BofA Securities has revised its price target for Johnson & Johnson, traded on the NYSE as JNJ, elevating it from $263 to $278 while retaining a Neutral stance. The adjustment follows upward revisions for Icotyde and incorporated updates regarding recent in-process research and development expenses. J&J stock experienced a 0.22% decline during premarket trading. For the upcoming third quarter, BofA projects revenue of $25.5 billion, matching consensus expectations, but anticipates earnings per share of $2.53, which sits 12% under Wall Street forecasts. The financial institution models an overall top-line expansion of 6%, driven by a 7% rise in pharmaceuticals and a 4% increase in medical technology. Furthermore, reports indicate that J&J is currently engaged in discussions with Apollo Global Management concerning the potential divestiture of its orthopedics division, a transaction potentially valued at close to $20 billion.
AI 시장 분석
BofA raised Johnson & Johnson's (JNJ) price target to $278, but projected Q3 earnings per share (EPS) at $2.53, which is 12% below the consensus. Q3 revenue is expected at $25.5 billion, reflecting the dilutive effect of research and development (R&D) expenses. This price target increase is driven by a revaluation of the defensive sector, and investors should monitor both short-term earnings weakness and the growing trend in new drug prescriptions.
상승 영향
- Biotech — J&J's Tremfya and Caplyta prescription volumes surged 50% and 60% year-over-year respectively, driving expectations for 6% revenue growth centered on new drugs.
하락 영향
- Biotech — Q3 EPS is projected at $2.53, missing the market consensus by 12%, and an R&D cost dilution of $0.64 puts pressure on short-term earnings.
DYAX 전담 분석
BofA's downward revision of Q3 EPS estimates could exert short-term downward pressure on JNJ's stock price, but the raised price target reflects an upward valuation for 2027 and a preference for defensive stocks. In particular, the surge in prescription volumes for Tremfya and Caplyta is positive, though R&D cost burdens are a factor pressing short-term earnings.
The bullish scenario involves sustained revenue growth in the pharmaceutical and medtech sectors (7% and 4% respectively) and the successful divestiture of the orthopedics business (valued at approximately $20 billion) enhancing corporate value. The bearish scenario occurs if R&D cost dilution is greater than expected and Q3 earnings underperformance triggers a stock correction, with future prescription data and restructuring progress serving as key monitoring indicators.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 43% · Bearish (Short) 57%
505 participants
Related News
- JPMorgan Downgrades Monday.com to Neutral Amid Growth Moderation
- US 10-Year Treasury Yield Nears 2007 Peak, Just 2 Basis Points Away
- DYAX Analysis: Three Volatile Equities to Approach with Caution
- OpenAI Sought to Make $100 Million Investment in Hugging Face
- Here Is Exactly How Much a $10,000 Investment in Coca-Cola Since 1988 Yields
- How Tesla Semi Could Add Billions to the EV Maker's Financials
